This article summarized the latest R&D progress of Metyrosine, the Mechanism of Action for Metyrosine, and the drug target R&D trends for Metyrosine.

Novartis reported FDA's approval of Cosentyx® (secukinumab) for the management of moderate to extreme hidradenitis suppurativa in adult patients.

This article summarized the latest R&D progress of Mexazolam, the mechanism of action for Mexazolam, and the drug target R&D trends for Mexazolam.

The FDA has given its sanction for Wezlana (ustekinumab-auub), considering it a biosimilar and substitute for Stelara (ustekinumab) in treating several inflammatory conditions.

In a hairpin sequence, the strand loops out and then come back to pair with itself, forming a double helix (the stem) ending in an unpaired loop.

The U.S. Food and Drug Administration (FDA) has given permission to resume the Phase 1 clinical trial of XMT-2056, according to Mersana Therapeutics, Inc., a biopharmaceutical firm in the clinical stage.

This article summarized the latest R&D progress of Midodrine Hydrochloride, the Mechanism of Action for Midodrine Hydrochloride, and the drug target R&D trends for Midodrine Hydrochloride.

Lirum Therapeutics announces encouraging results on LX-101, an innovative, clinical-phase targeted treatment, showing significant preliminary efficacy against children's sarcomas.

A fusion protein is a protein composed of at least two domains that are encoded by separate genes fused together so that they are transcribed and translated as a single unit, producing a single polypeptide.

Context Therapeutics has revealed promising preclinical results for its research asset, CTIM-76.

This article summarized the latest R&D progress of Glycyrrhetinic Acid, the mechanism of action for Glycyrrhetinic Acid, and the drug target R&D trends for Glycyrrhetinic Acid.

Chimeric Therapeutics has disclosed that the US FDA has given the green light to the IND submission for CHM 2101.